(Adnkronos) - “La psoriasi è molto impattante. È necessario che oggi un paziente possa e debba avere un trattamento per riprendersi la propria vita. I farmaci che abbassano il burden infiammatorio, inoltre, aiutano a ridurre i rischi di comorbilità associate. Questa nuova molecola (deucravacitinib) può aiutare i pazienti a riprendersi la loro vita, perché spesso a causa della psoriasi evitano le relazioni sociali". Lo afferma Maria Concetta Fargnoli, professoressa di Dermatologia presso l’università dell’Aquila (UnivAq) e vicepresidente di Sidemast (Società italiana di dermatologia e delle malattie sessualmente trasmesse) durante la conferenza stampa organizzata da Bristol Myers Squibb per annunciare il via libera di Aifa alla rimborsabilità di deucravacitinib per il trattamento della psoriasi da moderata a severa.
Category
🗞
NewsTranscript
00:00At the moment, we have several therapies available for patients, focusing on those with moderate to severe psoriasis.
00:12We have conventional drugs, which certainly have the limit in terms of effectiveness, but above all of long-term treatment for toxicity, and then we have innovative drugs.
00:23In the field of innovative drugs, we have biologics and small molecules.
00:27Today, we have the latest generation of biologics, which are very, very effective, but are often perceived by the patient as very strong drugs.
00:38In short, this is what the patient tells us, which often requires, especially in moderate forms, a treatment that is less aggressive.
00:47On the other hand, we must bear in mind that these innovative drugs are not effective in all patients, and above all they do not maintain their effectiveness in the long-term treatment, with an inefficiency that can be primary or secondary.
01:04Therefore, from various interviews with patients, it has emerged that there is a need for new drugs, especially for a first level of innovative therapy that can meet all the requirements and also complete patients who may not be responders to the therapies already carried out.
01:27I would define psoriasis as more than invalidating, it is very impactful, in the sense that, from the point of view of quality of life, both relational and also work-related, in their daily life, they have a very strong impact on quality of life.
01:44So, it is obvious that today it is absolutely necessary that a patient can and must have their own treatment, because this allows them to resume their life, to restart their life in their normality.
02:06In addition to the fact that using drugs that lower the inflammatory burden of the patient can also help in the reduction of associated comorbidities, which very often can compromise the patient's life.